Gabapentin & pregabalin
At a glance
- Medicare prescriptions, 2024
- 41,838,535
- Medicare drug cost
- $738.1M
- Average cost per prescription
- $17.64
- Clinicians who prescribed it
- 368,776
Where it is prescribed
What these drugs are
Gabapentin and pregabalin treat nerve pain and seizures. Pregabalin is a controlled substance.
Who prescribes it
- Family Medicine 25.6%
- Nurse Practitioners 20.2%
- Internal Medicine 19.5%
- Physician Assistants 7.7%
- Pain Medicine 5.4%
- Neurology 4.6%
- General Practice 2.1%
- Physical Medicine & Rehabilitation (PM&R) 1.9%
- Psychiatry 1.6%
- Rheumatology 1.6%
- Geriatric Medicine 1.3%
- Psychiatric Nurse Practitioners 1.2%
Share of Medicare prescriptions written by each specialty.
Drugs in this group
| Drug | Prescriptions |
|---|---|
| Gabapentin (Gralise, Neurontin) | 35,085,700 |
| Pregabalin (Lyrica Cr, Lyrica) | 6,738,395 |
| Gabapentin Enacarbil (Horizant) | 14,647 |
Drugs filled in fewer than 1,000 counties have no page of their own; their national totals are shown here.
Industry payments about this drug
Drug makers reported $52,840 in payments to clinicians that named this group of drugs in 2025 (meals, speaking, consulting and similar).
- Azurity Pharmaceuticals, Inc. $51,107
- Mylan Inc. $1,733
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
10 recalls since 2020
- Oct 2025 · The Harvard Drug Group LLC · Class II
Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity. - Jun 2025 · The Harvard Drug Group LLC · Class II
Defective container; blister packaging inadequately sealed. - Mar 2025 · Glenmark Pharmaceuticals Inc., USA · Class II
CGMP Deviations - Mar 2025 · Sun Pharmaceutical Industries Inc · Class III
Cross Contamination - May 2024 · Rising Pharma Holding, Inc. · Class III
Presence of Foreign Tablets/Capsules: Complaint received from a re-packager, American Health Packaging (AHP), where a foreign tablet was discovered in one of the bottles during packaging set up. Tablet identified as pantoprazole tablet 20mg. - Apr 2023 · The Harvard Drug Group · Class III
Product mixup: one foreign tablet found in product. - Oct 2021 · Sun Pharmaceutical Industries Inc · Class II
Failed Tablet/Capsule Specifications: Out of Specification results for particle Size Distribution and Bulk Density of the Active Pharmaceutical Ingredient. - Mar 2021 · Cardinal Health Inc. · Class II
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.